Last updated on July 2019

Evaluation of Major Cardiovascular Events in Patients With or at High Risk for Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo

Brief description of study

The purpose of this study is to determine if treatment with bempedoic acid (ETC-1002) versus placebo decreases the risk of cardiovascular events in patients who are statin intolerant.

Clinical Study Identifier: NCT02993406

Find a site near you

Start Over

Maggie Horner, BA, MBA

Blumenau, Brazil
  Connect »